Breast Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal Cancer, HER-2 Protein Overexpression, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Salivary Gland Cancer, Urothelial Carcinoma
Conditions
Keywords
JZP598, ZW25, HER2 IHC 3+ Overexpression Solid Tumors
Brief summary
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Interventions
DRUGZanidatamab
Administered by intravenous (IV) infusion
Sponsors
Jazz Pharmaceuticals
Jazz Pharmaceuticals Ireland Limited
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Is at least 18 years of age inclusive at the time of signing the informed consent 2. Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with HER2-targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required. 3. HER2 overexpression (IHC 3+) must be determined by a sponsor designated central laboratory. 4. All participants must have adequate tumor sample for submission to allow central HER2 testing. 5. Presence of at least 1 measurable lesion as assessed by Independent Central Review (ICR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) 6. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Has a life expectancy of at least 3 months, in the opinion of the investigator. 8. Participants with history of treated and stable CNS metastases are eligible, provided the following criteria are met: 1. Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS. 2. Participants with treated CNS metastases that are no longer symptomatic may be included in the study if they recovered to \< Grade 1 (CTCAE Version 5.0 or higher) or baseline from the acute toxic effect associated with the treatment \> 7 days prior to Cycle 1 Day 1. 3. Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention. 9. Adequate organ functions. 10. Females of childbearing potential must have a negative pregnancy test result. 11. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.
Exclusion criteria
1. Has known or suspected leptomeningeal disease and/or untreated brain metastasis. 2. Has uncontrolled or significant cardiovascular disease 3. Has ongoing toxicity related to prior cancer therapy 4. Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals. 5. Has known Human Immunodeficiency Virus (HIV) infection. 6. Has active hepatitis B or C infection. 7. Has an active SARS-CoV-2 infection. 8. Has a history of life-threatening hypersensitivity to monoclonal antibody (mAbs) or to recombinant proteins or excipients in the drug formulation of zanidatamab. 9. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site. 10. Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study. 11. Prior treatment with HER2-targeted therapy (Cohort 1 only). 12. Has a history of trauma or major surgery 13. Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1. 14. Received zanidatamab at any time prior to the current study. 15. Colorectal Cancer (CRC) participants with known KRAS/NRAS and BRAF mutations. 16. Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion. 17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy. 18. Prior or concurrent invasive malignancy other than the disease under study, whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Up to 2.5 years | The Independent Central Review (ICR) assessed cORR is defined as the proportion of participants who had a best overall response of Complete Response (CR), or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) Per RECIST Version 1.1, as assessed by ICR | Up to 2.5 years | ICR assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented progressive disease (PD) per RECIST v1.1 or death from any cause. |
| cORR by RECIST Version 1.1, as assessed by Investigator | Up to 2.5 years | Investigator assessed cORR is defined as the proportion of participants who had a best overall response of Complete Response (CR), or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) |
| Duration of Response (DOR) Per RECIST Version 1.1, as assessed by Investigator | Up to 2.5 years | Investigator assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented progressive disease (PD) per RECIST v1.1 or death from any cause. |
| Time to Response (TTR), as assessed by ICR | Up to 2.5 years | ICR assessed TTR is defined as the time from the first dosing date to the first objective response (CR or PR) per RECIST v1.1. |
| Time to Response (TTR), as assessed by Investigator | Up to 2.5 years | Investigator assessed TTR is defined as the time from the first dosing date to the first objective response (CR or PR) per RECIST v1.1. |
| Disease control rate (DCR), as assessed by ICR | Up to 2.5 years | ICR assessed DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed CR, or PR, or stable disease using the RECIST version 1.1 criteria |
| Disease control rate (DCR), as assessed by Investigator | Up to 2.5 years | Investigator assessed DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed CR, or PR, or stable disease using the RECIST version 1.1 criteria |
| Progression Free Survival (PFS), as assessed by ICR | Up to 2.5 years | PFS is defined as the time in months from the first dosing date to the date of first documented disease progression (as assessed by ICR according to RECIST v1.1) or death from any cause, whichever occurs first. |
| Progression Free Survival (PFS), as assessed by Investigator | Up to 2.5 years | PFS is defined as the time in months from the first dosing date to the date of first documented disease progression (as assessed by Investigator according to RECIST v1.1) or death from any cause, whichever occurs first. |
| Overall Survival (OS) | Up to 3.5 years | OS is defined as the time in months from randomization to the date of death due to any cause. |
| Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) As Graded by NCI CTCAE Version 5.0 | Up to 2.5 years | — |
| Number of Participants With Dose Reductions | Up to 2.5 years | — |
| Number of Participants Discontinuing Study Treatment Due to TEAEs | Up to 2.5 years | — |
| Serum Concentrations of Zanidatamab | Up to 2.5 years | — |
| Number of Participants Positive for Anti-drug Antibodies to Zanidatamab | Up to 2.5 years | — |
| Number of participants reporting Symptomatic Adverse Events based on Patient-reported Outcome-Common Terminology Criteria for AEs (PRO-CTCAE) | Up to 2.5 years | — |
| Number of participants reporting Symptomatic Adverse Events based on European Organisation for Research and Treatment of Cancer (EORTC) Item Library | Up to 2.5 years | — |
| Percentage of all treated participants reporting overall side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5) | Up to 2.5 years | — |
| Percentage of time when participants on treatment reported a high side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5) | Up to 2.5 years | — |
Countries
South Korea, Spain, United States
Contacts
CONTACTClinical Trial Disclosure & Transparency
Outcome results
None listed